Nonsteroidal anti-inflammatory drugs show chemopreventive efficacy in colon cancer, but the mechanism behind this remains unclear. Elucidating this mechanism is seen as vital to the development of new chemopreventive agents. We studied the effects of aspirin on the oncogenic Wnt/b-catenin pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of b-catenin by immunoblotting. Furthermore, the ubiquitination and cytoplasmic levels of b-catenin were assessed by immunoblotting, and also the localization of b-catenin was shown by green fluorescent protein-tagged b-catenin and time-lapse fluorescent imaging. Importantly, aspirin treatment caused increased phosphorylation of protein phosphatase 2A (PP2A), an event associated with inhibition of PP2A enzymatic activity, which was confirmed by a reduction in enzymatic PP2A activity. Moreover, this inhibition of PP2A enzymatic activity was essential for the effects of aspirin on the Wnt/b-catenin pathway as shown by transient transfection with PP2A constructs. The findings in this article provide a molecular explanation for the efficacy of aspirin in chemoprevention of colorectal cancer and shows biochemical evidence that PP2A is an important regulator of Wnt/b-catenin pathway activity in these cells.
Introduction
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce death rates due to colon cancer (Thun et al., 1991) and to reduce the size of colonic adenomatous polyps (Labayle et al., 1991) , both in animal and in human studies (Husain et al., 2002 and references therein). These findings suggest that chemoprevention of colon cancer may be a possible way of reducing the impact of this increasingly common and frequently fatal disease. There remain, however, serious problems with the widespread use of NSAIDs in those at risk for the development of colon cancer. The incidence of side effects such as gastrointestinal haemorrhage and renal damage preclude their use in this setting. The development of drugs with similar efficacy in colon cancer with acceptable side effects is in process. Understanding the mechanism of action of NSAIDs in colon cancer is an essential step in this process.
The original and still the leading theory is that NSAIDs act through their ability to block cyclooxygenase (COX) enzymes. However, related compounds with no COX-inhibitory activity retain their antitumour activity (Charalambous and O'Brien, 1996) , and cancer cells lacking COX-2 enzyme are still sensitive to these compounds (Hanif et al., 1996) . Therefore, COX-independent effects of NSAIDs in colon cancer have been postulated (reviewed in Tegeder et al., 2001) such as their ability to block peroxisome proliferation activator delta (He et al., 1999) , inhibition (Kopp and Ghosh, 1994) or activation (Stark et al., 2001 ) of nuclear factor kb and effects on the TGF-b family member, macrophage inhibitory cytokine (Baek et al., 2001) . A more direct explanation of the effects of NSAIDs in colon cancer would be that they target elements within the most essential oncogenic pathway in colon cancer, the Wnt/b-catenin pathway.
An activating mutation of the Wnt/b-catenin pathway is the first step in almost all colorectal cancers. Here, the essential feature is an increase in the levels of free cytoplasmic b-catenin (reviewed in Miller et al., 1999) . In most cases, Wnt/b-catenin pathway activation is brought about by a mutation in the adenomatous polyposis coli (APC) gene (reviewed in Polakis, 1997) .
This leads to a truncated APC protein that cannot perform its function as part of the b-catenin destruction complex, which in turn leads to reduced b-catenin degradation and abnormally high levels of cytoplasmic b-catenin. This stabilized b-catenin translocates to the nucleus where it binds with members of the T-cell factor (Tcf)/lymphoid enhancer factor (Lef) family of transcription factors, and activates the transcription of Wnt target gene expression such as cyclin D and Myc (Mann et al., 1999) . In many of the remaining cases, mutations in b -catenin itself at sites of glycogen synthase kinase-3b (GSK3b) phosphorylation leads to its cytoplasmic accumulation and Wnt/b-catenin pathway activation (Morin et al., 1997) .
We set out to further investigate the effects of NSAIDs on the Wnt/b-catenin pathway in colon cancer cells. A reduction in the constitutive activity of this pathway in colon cancer, for example by reducing levels of signalling b-catenin, reverses this earliest and most essential oncogenic signal and has been shown to be an effective antitumour strategy in vitro and in vivo Roh et al., 2001) .
Evidence has been building that there may be direct effects of NSAIDs on this pathway (Kishimoto et al., 2000; Smith et al., 2000; Dihlmann et al., 2001) . This would concur with the epidemiological data that suggest NSAIDs act at a very early stage in colon cancer and must be given at this earliest point in the disease process to be effective (Giovannucci et al., 1995) . Here, we provide evidence that NSAIDs inhibit the Wnt/ b-catenin pathway by stimulating the phosphorylation and breakdown of b-catenin.
Furthermore, the precise biochemical mechanism by which the b-catenin degradation complex is regulated is not yet known. Alterations in protein phosphorylation states are likely to be central to this regulation, because all the elements of the b-catenin degradation complex are phospho-proteins. The phosphorylation status of a protein is determined by the relative activities of both kinases and phosphatases. A number of protein kinases have been shown to influence Wnt/b-catenin signalling, including GSK3b, protein kinase C, and casein kinase I and II (Seidensticker and Behrens, 2000) . The protein phosphatases involved have received less attention. However, in Xenopus laevis axis formation the catalytic subunit of the serine/threonine protein phosphatase 2A (PP2A) exerts a positive role on Wnt/b-catenin pathway activity whereas the inhibitory regulatory B56 subunit of PP2A exerts a negative influence on Wnt/b-catenin signalling in mammalian cells and Xenopus embryo explants (Seeling et al., 1999; Ratcliffe et al., 2000) . Mutations in PP2A subunits in various types of cancer, including colon cancer, have also been described, but their precise role in the cancerous process is as yet unknown (reviewed in Schonthal, 2001) .
For these reasons, we decided to study the effect of aspirin on the Wnt/b-catenin pathway and the role of PP2A in these effects. Our results show that aspirin inhibits Wnt pathway activity at the level of PP2A enzymatic activity, providing a possible molecular mechanism for aspirin effects in chemoprevention.
Results
Aspirin downregulates constitutively active b-catenin/Tcf signalling shown by TCF reporter assay and the expression of Wnt/b-catenin targets in APC mutant cells The Wnt/b-catenin pathway acts to control the transcription of genes through the binding of a complex of b-catenin and TCF to specific promoter elements. The activity of this final step in the Wnt/b-catenin pathway can be measured using a luciferase reporter construct (van de Wetering et al., 1997) . SW480 cells were transiently transfected with the pTOPFLASH or pFOPFLASH (containing a 'far from optimal' TCF binding site) construct together with a pCMV-Renilla luciferase construct to act as an internal control for transfection efficiency and potential toxicity of treatments. Figure 1a shows that aspirin downregulates the constitutively active b-catenin/TCF signalling in SW480 cells in a dose-dependent manner. The specificity of the aspirin effect on TCF reporters was confirmed by the fact that pFOPFLASH was not influenced by aspirin (data not shown). Similar results were obtained in a second colon cancer cell line, DLD-1, and using a second NSAID, indomethacin (data not shown). Comparable data on TOPFLASH/FOPFLASH reporter assays with aspirin and indomethacin were also shown by Dihlmann et al. (2001) . To confirm that aspirin inhibits Wnt/b-catenin pathway activity, protein levels of various Wnt/b-catenin targets were assessed by immunoblotting. As shown in Figure 1b and c, aspirin treatment induces a decrease of the expression of c-myc, CD44 variant 3, c-met and cyclin D1 in SW480 cells, all proteins known to be in influenced via the Wnt/ b-catenin pathway (Morin, 1999; Boon et al., 2002) . DLD-1 and SW480 cell lines both harbour APC mutations and express wild-type b-catenin. To study the effect of aspirin on b-catenin mutated cells, we performed a TOPFLASH/FOPFLASH assay and analysed the expression of Wnt targets in HCT116 cells, a cell line expressing wild-type APC and a mutant b-catenin (mutations described in Morin et al., 1997) . As shown in Figure 1d , aspirin has no effect on the b-catenin/TCF transcriptional activity and or on the expression of Wnt targets in b-catenin mutated HCT116 cells.
Aspirin leads to increased the phosphorylation of Se41/Thr45 of b-catenin Having shown that Wnt/b-catenin pathway activity is downregulated by aspirin, we looked further at which elements within this pathway are affected. A central element within this pathway is b-catenin. It is the excess of cytoplasmic b-catenin that leads to the overactivity of the Wnt/b-catenin pathway seen in colon cancer (Munemitsu et al., 1995; Orford et al., 1997) . Control of the size of this pool is regulated by the phosphorylation of b-catenin. This phosphorylation then targets b-catenin for ubiquitination and degradation by the 26S proteasome, and thus this phosphorylation is the limiting event in Wnt/b-catenin signalling. We assessed the effect of aspirin on b-catenin phosphorylation and as seen in Figure 2 , a dose- (Figure 2a ) and time-related ( Figure 2b ) increase in b-catenin phosphorylation is induced after aspirin treatment. The activity of GSK3b is controlled by its phosphorylation. We therefore assessed the activity of this kinase using phosphospecific antibodies in SW480 cells treated with aspirin. No alteration in the phosphorylation levels of GSK3b was observed with aspirin ( Figure 2a) , suggesting that the increase in phosphorylated b-catenin observed is GSK3b independent. These experiments were repeated with similar results in the DLD-1 colon cancer cell line suggesting the effect is not cell type specific (not shown). These results back up findings of Dihlmann et al. (2003) . To confirm that the phosphorylation of b-catenin is GSK3b independent, SW480 cells were pretreated with LiCl, a potent and well-known inhibitor of GSK3b (Orena et al., 2000) . Briefly, SW480 cells were pretreated with LiCl before the aspirin treatment. Hereafter the phosphorylation status of b-catenin was assessed by immunoblotting, which showed no change in the effect of aspirin on the phosphorylation of this protein (data not shown). Furthermore, nuclear extracts of SW480 cells pretreated with LiCl before the aspirin treatment showed no differences in downregulation of the nuclear b-catenin expression compared to nuclear extracts of aspirin treated SW480 cells (data not shown). These findings confirm those of Dihlmann et al. (2003) and are therefore not presented here.
Aspirin leads to a reduction in cytoplasmic b-catenin levels in APC mutated cells Phosphorylation of b-catenin classically leads to its ubiquitination and breakdown. We initially tried to confirm this by blotting for total b-catenin in whole-cell lysates of SW480 cells treated with aspirin. As shown in Figure 2 , total b-catenin levels remained unchanged while there was a convincing increase in b-catenin phosphorylation seen on the same blots. b-Catenin exists in two main cellular pools, a structural pool important for the cytoskeleton and a smaller free cytoplasmic pool. It is only this latter pool that plays a part in the Wnt/b-catenin pathway. We therefore analysed the effect of aspirin on the cytoplasmic pool of b-catenin (S100 cellular fraction), according to the Aspirin, PP2A and the Wnt/b-catenin pathway CL Bos et al method of Orford et al. (1997) , and as shown in Figure 3a , the cytoplasmic pool decreases in a dosedependent manner upon the addition of aspirin. This effect is also seen with indomethacin in the DLD-1 cell line (not shown).
To confirm this effect of reduction of b-catenin in the cytoplasmic pool, we used green fluorescent protein (GFP)-tagged b-catenin and visualized the effect of aspirin in real time using a fluorescent microscope and time-lapse imaging in a single living colon cancer cell. Addition of aspirin led to a 40% reduction in cytoplasmic b-catenin levels as seen in Figure 3b .
To investigate whether the effects seen on b-catenin are dependent on intact b-catenin, we investigated the b-catenin mutant HCT116 cell line. As shown in Figure 3c , aspirin treatment did no lead to a reduction in cytoplasmic b-catenin levels. This confirms the unchanged activity of the Wnt/b-catenin pathway as shown by the TOPFLASH assay ( Figure 1a ) and Wnt/ b-catenin target protein levels ( Figure 2c ).
Aspirin leads to an increase in ubiquitinated b-catenin b-Catenin is marked for degradation by the 26S proteasome by the covalent addition of ubiquitin. This task is performed by the SCF ubiquitin ligase complex, which contains a component, b-TrCP that binds specifically to phosphorylated b-catenin. To confirm that the reductions in cytoplasmic b-catenin levels are indeed brought about by this mechanism, we assessed the effect of aspirin treatment on the appearance of higher molecular weight ubiquitinated b-catenin protein. We immunoprecipitated b-catenin from SW480 cells (untreated or treated with 5 mM aspirin Immunoblot of cytoplasmic extracts (S100) and the noncytoplasmic fraction (P100) of SW480 cells treated with aspirin using anti-b-catenin or anti-b-actin antibodies. The graph shows the relative amounts of b-catenin corrected for b-actin loading controls. The cytoplasmic pool of b-catenin is only one quarter of the size of the noncytoplasmic pool demonstrating why b-catenin analysis in whole-cell lysates may not adequately reflect changes in the cytoplasmic pool. (b) Analysis of the mean fluorescence of the cytoplasm and nucleus of a single SW480 cell transiently transfected with GFP-tagged b-catenin followed over time after treatment with aspirin (10 mM) at time ¼ 0. Cells were grown to 80% confluence on glass coverslips and then transiently transfected with GFP-tagged b-catenin and further cultured overnight. The following day single GFP-expressing cells were centred under a fluorescent microscope and a series of images taken automatically using time-lapse fluorescent imaging. The mean fluorescence of a selected area within the nucleus or cytoplasm was analysed using image analysis software for the series of images. (c) Immunoblot of cytoplasmic extracts (S100) and the noncytoplasmic fraction (P100) of HCT116 cells treated for 16 h with aspirin using anti-b-catenin or anti-b-actin antibodies.
Aspirin, PP2A and the Wnt/b-catenin pathway CL Bos et al for one hour) and then probed the blotted immunoprecipitate with antiubiquitin antibodies according to the method of Kitagawa et al. (1999) . Figure 4 shows the appearance of an ubiquitin immunoreactive ladder extending upwards from the 97 kDa height of non-ubiquitinated b-catenin, induced by the addition of aspirin. Furthermore, when proteasomal activity is inhibited by a proteasome inhibitor MG132, the inhibiting effect of aspirin on b-catenin/TCF transactivation is abolished, supporting the concept that aspirin acts on the Wnt/b-catenin pathway via a proteasome-dependant mechanism (data not shown).
Aspirin leads to increased phosphorylation of Tyr307 of PP2A thereby inhibiting the PP2A enzymatic activity While trying to identify the cause of aspirin-induced phosphorylation of b-catenin, we found no evidence for increased activity of the kinase GSK3b with aspirin. This led us to think that aspirin might act as a phosphatase inhibitor. In support of this, we see high levels of phosphorylation of b-catenin when cells are treated with a known phosphatase inhibitor, calyculin A ( Figure 2 ). This suggests that aspirin inhibits the activity of a phosphatase rather than stimulating a kinase to stabilize the phosphorylation of b-catenin. Taking this together with new evidence that has emerged that PP2A is a possible regulator of the Wnt//b-catenin pathway in colon cancer cells (Seeling et al., 1999; Ratcliffe et al., 2000) , we were prompted to investigate a possible effect of aspirin on PP2A activity. To this end we evaluated the phosphorylation status of the inhibitory Tyr307 in PP2A by immunoblotting. As evident from Figure 5a , aspirin treatment resulted in a time-and dose-dependent increase of phosphorylation of PP2A at this amino-acid residue. These results suggest that aspirin negatively influences PP2A enzymatic activity. To establish whether increased Tyr307 phosphorylation actually corresponds with reduced PP2A activity we performed the malachite green assay. In this assay, PP2A activity is measured by the release of P i from the synthetic substrate KIpTIRR. Since this assay cannot fully differentiate between PP1 and PP2A activity, PP2A was purified by immunoprecipitation and these samples were used for the malachite green assay. As evident from Figure 5b , in both DLD-1 and SW480 cells, treatment with 5 mM aspirin in a time course of 60 min resulted in reduced PP2A enzymatic activity that is consistent with the effects of aspirin on the b-catenin phosphorylation.
We also investigated the effect of aspirin on PP2A activity in the b-catenin mutant cell line HCT116. As shown in Figure 5c , aspirin treatment results in a decreased activity of PP2A in HCT116 cells. Together these data show that aspirin reduces PP2A enzymatic activity in all the cell lines tested but that this only leads to reduced Wnt/b-catenin-pathway activity in cells with wild-type b-catenin.
PP2A enzymatic activity is essential for the effect of aspirin on b-catenin phosphorylation To investigate whether PP2A is an essential mediator of aspirin effects on the Wnt/b-catenin pathway, we employed okadaic acid, a well-known inhibitor of PP2A. Briefly, DLD-1 and SW480 cells were preincubated with 100 nM Okadaic Acid (concentration commonly used in cell-based assays (Mistry et al., 1998; Xie et al., 1998) , which efficiently inhibits PP2A without affecting protein phosphatase 1 (PP1) (Favre et al., 1997; Nunbhakdi-Craig et al., 2002; Smal et al., 2004) ), or with vehicle control. Cells were subsequently incubated with aspirin (5 mM) in the presence of Okadaic acid or vehicle control during a time course (as indicated). In agreement with a role for PP2A in controlling b-catenin phosphorylation, we observed that treatment with okadaic acid alone increases the phosphorylation of b-catenin ( Figure 6a ). As already shown in Figure 2a and b, a time-and dose-dependent increase of phosphorylation of b-catenin is shown in cells treated with aspirin and vehicle control (left panels of Figure 6a ). This time-and dose-dependent increase of phosphorylated b-catenin is no longer seen after preincubation with okadaic acid and the subsequent incubation with aspirin (in the presence of okadaic acid) (right panels Figure 6a ). This suggests that aspirin leads to increased phosphorylation of b-catenin by inhibiting PP2A.
To further investigate whether the increased phosphorylation of b-catenin is directly linked to the increased phosphorylation of Tyr307 and, thus, inhibition of PP2A, DLD-1 cells were transiently transfected with an N-terminal triple (HA)-tagged PP2A catalytic subunit C construct (Chung et al., 1999) . A wild-type catalytic subunit ((HA) 3 -C WT ) construct served as a control and a construct in which Tyr307 of the catalytic subunit is mutated to a phenylalanine ((HA) 3 -C Y307F ) to eliminate this site of phosphorylation. As expected, we observed an increase of phosphorylation of b-catenin after h incubation with 5 mM aspirin in the nontransfected cells (Figure 6b ). The same effect is seen in cells that were transiently transfected with the wild-type construct. In the cells that were transiently transfected with the mutated construct, phosphorylated b-catenin is Figure 4 Aspirin leads to an increase in ubiquitinated b-catenin. Cell lysates of SW480 cells with or without 5 mM aspirin treatment for 1 h were immunoprecipitated with anti-b-catenin antibodies and then immunoblotted using antiubiquitin antibodies. The blot was then stripped and reprobed using anti-b-catenin antibodies to show that equal amounts of protein had been immunoprecipitated.
Aspirin, PP2A and the Wnt/b-catenin pathway CL Bos et al seen in untreated cells, as expected. Furthermore, in these cells transfected with the mutated PP2A construct, no effect of aspirin was observed (Figure 6b ), suggesting that Tyr307 is the target of aspirin. In addition, to test the effect of PP2A inhibition in a functional assay, we performed a TOPFLASH assay in DLD-1 cells. DLD-1 cells were transiently transfected with pTOPFLASH, pCMV-Renilla (to serve as an internal control) and either with a wild-type or mutant PP2A construct (the same constructs were used in Figure 6b ) and after treatment with aspirin for 6 h the b-catenin/TCF transcriptional activity was assessed. As shown in Figure 6c , aspirin reduced the b-catenin/TCF transcriptional activity in cells transfected with the wild-type construct. Transfection with the mutant construct reduced b-catenin/TCF transcriptional activity compared to the cells transfected with the wild-type PP2A construct. Transfection with the mutant construct reduced b-catenin/TCF transcriptional activity to the same level as wild-type transfected cells treated with aspirin. Furthermore, the b-catenin/TCF activity in the cells transfected with the mutant construct was not affected by aspirin treatment. We conclude that treatment of colon cancer cell lines with aspirin promotes b-catenin phosphorylation by inactivating PP2A. This is achieved by promoting the phosphorylation of Tyr307 on the catalytic subunit of PP2A thereby inactivating it.
Discussion
Understanding of the mechanism of action of NSAIDs in colon cancer is seen as the key to developing new more effective chemopreventive treatments with fewer side effects. Most of the investigation has focused on COX enzymes 1 and 2 with the accumulation of genetic and pharmacologically derived data to support the importance of COX-2 in the progression of colon cancer (Oshima et al., 1997; Steinbach et al., 2000) . However, more and more evidence emerges that NSAIDs have a wide range of targets other than COX (Tegeder et al., 2001) , and this coupled with evidence mitigating against an essential role for COX-2 has led several investigators to propose COX-independent mechanisms for the action of NSAIDs in colon cancer. In the present study, we provide evidence that aspirin acts through PP2A inhibition to increase b-catenin phosphorylation thereby reducing Wnt/b-catenin pathway activity. (c) DLD-1 cells were transiently co-transfected with pTOPFLASH, pCMV-Renilla and wild type or mutant PP2A constructs overnight (more information in Materials and methods). The transfection was followed by 5 mM aspirin treatment for 6 h. Afterwards, cells were lysed and analysed using the luciferase assay system (Roche). Incubations were performed in triplicate and experiments were repeated two times. The presented results are represented as percentages compared to the untreated cells transfected with pTOPFLASH, pCMV-Renilla (to serve as an internal control) and wild-type PP2A construct, normalized to the internal control.
Aspirin, PP2A and the Wnt/b-catenin pathway CL Bos et al
We set out to investigate whether NSAIDs have direct effects on the Wnt/b-catenin pathway and elements within it. Constitutive activation of this pathway is found in almost all colon cancers. Mutations leading to truncation of the APC protein or in b-catenin itself lead to disruption of normal b-catenin breakdown, increasing free cytoplasmic b-catenin, which translocates to the nucleus to bind with TCF and switch on Wnt/b-catenin target gene expression. The level of free cytoplasmic b-catenin is controlled largely by its ubiquitination and breakdown by the proteasome (Orford et al., 1997) . We first used a TCF reporter assay to assess the effects of NSAIDs on the activity of the pathway as a whole. We then used immunoblotting using phosphospecific antibodies to detect changes in the level of phosphorylated b-catenin and GSK3b. We found a time and concentration dependent increase in b-catenin phosphorylation. Importantly, this effect was seen at micromolar concentrations of aspirin. Proponents of the COX-2 theory have voiced doubts over the relevance of COX-independent actions of NSAIDs, which require high doses (millimolar) that they feel are not achievable in vivo (Gupta and DuBois, 1998; Marx, 2001) . However, human subjects given a short analgesic dose (600 mg qid) attain millimolar (0.05-1.13 mM) concentrations of salicylate (Stark et al., 2001 ) and up to 10 mM aspirin has been used by these investigators in cell culture. The increase in phosphorylation of b-catenin we show here was also reported by Dihlmann et al. (2003) . Furthermore, they suggest that inactivation of a phosphatase, rather than stimulation of a kinase is a possible cause of the increased phosphorylation seen. Indeed, we show here that aspirin reduces the enzymatic activity of PP2A.
An association between PP2A and the Wnt/b-catenin pathway in colorectal cancer has been made earlier, although the evidence presented to date has been mainly on a genetic level (Seeling et al., 1999; Ratcliffe et al., 2000; Schonthal, 2001) . This led us to investigate the effect of aspirin on PP2A as an explanation for the effects of aspirin on the Wnt/b-catenin pathway. In this manuscript, we directly show that PP2A enzymatic activity influences the phosphorylation status of b-catenin and that reduced PP2A activity may well explain the effects of aspirin on the Wnt/b-catenin pathway activity.
In summary, in the present study, we provide evidence that aspirin acts through PP2A inhibition to increase b-catenin phosphorylation thereby reducing Wnt/bcatenin pathway activity.
Materials and methods
Cell culture DLD-1, SW480 and HCT116 colon cancer cell lines were obtained from the ATCC, and cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Pailsey, Scotland) with 4.5 g/l Glucose and L-glutamine, which was supplemented with penicillin (50 U/ml) and streptomycin (50 mg/ml) and, were serum was used with 10% fetal calf serum (Gibco). Cells were grown in monolayers in a humidified atmosphere containing 5% CO 2 .
TOPFLASH assay
In Figure 1 , SW480 cells and DLD-1 cells were seeded in 24-well plates at 1 Â 10 5 cells/well. The following day cells were transiently transfected with 0.4 mg of the TCF reporter, pTOPFLASH (TCF Optimal Motif), or pFOPFLASH ('Far from OPtimal' motif) (van de Wetering et al., 1997) (pTOPFLASH and pFOPFLASH were gifts from Dr Hans Clevers (Utrecht University, The Netherlands)), and 0.008 mg of pCMV-Renilla luciferase (Promega, Madison, WI, USA) per well, using LipofectAMINE-Plus reagent according to the manufacturers instructions (Invitrogent life technologies) for 5 h. Hereafter, cells were incubated for 48 h in DMEM with 10% serum and no antibiotics containing various concentrations of aspirin.
In Figure 6c , DLD-1 cells were seeded in 24-well plates at 1 Â 10 5 cells/well are shown. The following day cells were transiently transfected overnight with 0.4 mg of the TCF reporter, pTOPFLASH, 0.008 mg of pCMV-Renilla luciferase (Promega), 0.8 mg (HA) 3 -C Y307F construct (more information see transient transfection with PP2A constructs) or control per well, using LipofectAMINE-2000t reagent according to the manufacturer's instructions (Invitrogent life technologies) overnight. Hereafter, cells were incubated for 6 h in DMEM with 10% serum and no antibiotics containing various concentrations of aspirin.
Samples were further prepared using the dual luciferase reporter kit (Roche, Mannheim, Germany), according to the manufacturer's instructions and luciferase levels measured using a dual injector luminometer.
Preparation of immunoblot samples DLD-1 or SW480 cells were seeded in six-well plates (Nalge Nunc, Denmark) and left to adhere for 24 h. The next day, at 60-80% confluence, cells were treated with aspirin (as indicated). Afterwards, cells were washed in ice cold phosphate buffered saline (PBS) and scraped into 200 ml of 3 Â sodium dodecyl sulphate (SDS)-sample buffer (125 mM Tris/HCl, pH 6.8; 4% SDS; 2% b-mercapto ethanol; 20% glycerol, bromphenol blue). Protein concentration was measured using the RC DC protein assay kit (Biorad, CA, USA), according to the manufacturer's instructions. Samples were stored at À201C.
Immunoblotting
Samples were boiled for 5 min at 951C followed by SDS-PAGE (polyacrylamide gel electrophoressis) and blotted onto PVDF membrane (Millipore). The blots were blocked with either 1% low-fat milk powder (for phospho-b-catenin, b-catenin, b-catenin (both obtained from Cell Signaling Technologyt, Beverly, MA, USA), b-actin, phopho-PP2A, PP1, ubiquitin (all obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA), and PP2A (BD Transduction Laboratoriest, San Jose, CA, USA) or 0.5% low-fat milk powder (for cyclin D1 (Neomarkers, Fremont, CA, USA), c-myc, c-met (both obtained from Santa Cruz Biotechnology) in Tris-buffered saline supplemented with 0.1% Tween-20 (TBST) for 1 h at room temperature and washed three times with TBST before overnight incubation at 41C with primary antibody in blocking buffer.
Subsequently, blots were washed three times for 10 min in TBST and incubated with, depending on used primary antibody, a secondary horseradish peroxidase-linked antibody (Goat-a-Mouse, Swine-a-Rabbit, Rabbit-a-Goat, all from DAKO, Glostrup, Denmark) for 1 h at room temperature in blocking buffer. Hereafter, the blots were three times washed in TBST and after chemoluminescence using Lumilight þ as a substrate, antibody binding was visualized using a LumiImager (both from Roche).
Cytoplasmic extraction
Cytoplasmic extractions were performed as described previously by Orford et al. (1997) . Briefly, SW480 or HCT116 cells were seeded in six-well plates and left to adhere for 24 h. The next day, at 60-80% confluence, cells were treated with 5 mM aspirin for 16 h, washed with ice-cold PBS and scraped into ice-cold lysis hypotonic buffer (10 mM Tris pH 7.4, 0.2 mM MgCl 2 , and 1 mM of Pefablock (Merck, Darmstadt, Germany)). Cell lysates were homogenized gently by passing it 10 Â through a 27 gauche needle and then centrifuged for 1 h at 100 000 g at 41C. The supernatant, designated S100, was removed and added to an equal volume of 3 Â SDSsample buffer, the resultant pellets, designated as P100, was taken up in diluted SDS-sample buffer to the same dilution as the S100 fraction for immunoblotting.
Real-time imaging of GFP-tagged b-catenin SW480 cells were seeded out overnight onto glass coverslips. The following day cells were transiently transfected with GFP-tagged b-catenin using LipofectAMINE-Plus reagent, according to the manufacturer's instructions and then grown overnight in DMEM with 10% serum. The following day single GFP-expressing cells were centered under a fluorescent microscope in a chamber containing medium at 371C. The medium was changed for medium with 10 mM aspirin 371C after 1 min, and the cells were followed for a further 3000 s with one image taken every 60 s.
Immunoprecipitation for ubiquitinated b-catenin determination SW480 cells were grown in monolayers and were incubated with 5 mM for 1 h. Afterwards, cells were washed in ice-cold PBS and scraped into ice-cold lysis buffer (150 mM NaCl, 0.5% Triton X-100, 5 mM ethylenediaminetetraacetic acid, 0.1% SDS, 0.5% sodiumdeoxycholate, 1 mM Pefablock) and incubated at 41C for 15 min. Cell lysates were then centrifuged for 5 min at 14 000 r.p.m. and supernatants were incubated overnight at 41C with anti-b-catenin antibodies (1:500). This was followed by incubation with protein-A sepharose beads (Sigma, St Louis, MO, USA) for 1 h at 41C. After centrifugation for 15 min at 14 000 r.p.m. at 41C, the beads were washed five times in ice-cold PBS before the addition of an equal volume of 3 Â SDS-sample buffer. Samples were used for immunoblotting using anti-ubiquitin antibodies.
Immunoprecipitation for PP2A activity determination DLD-1 and SW480 cells were grown in monolayers and were incubated with 5 mM aspirin for 60 min. Afterwards, total cellular proteins were extracted in a phosphate-free buffer (10 mM Tris/HCl, pH 7.6, 100 mM NaCl, 2 mM MgCl 2 , 1 mM CaCl 2 , 2 mM EGTA, 1% Triton X-100, 0.1 mM MnCl 2 , 0.1 mg/ ml BSA, 10 mg/ml leupeptin (Boehringer-Mannheim, Mannheim, Germany), 1 mg/ml aprotinin (Roche), 1 mM Pefablock) and sonicated for 10 s. Cell lysates were then centrifuged for 5 min at 14 000 r.p.m. at 41C. A-specific binding was blocked by preincubation for 2 h with protein-G sepharose beads (Sigma). After 5 min centrifugation at 14 000 r.p.m. at 41C, supernatants were incubated overnight at 4C with anti PP2A catalytic site a´antibodies (1:2000). This was followed by incubation with protein-G sepharose beads for 2 h at 41C. After centrifugation for 5 min at 14 000 r.p.m. at 41C, the beads were washed three times in ice-cold phosphate-free buffer before the addition of 200 ml phosphate-free buffer. Immunoprecipitates were used for PP2A activity determination.
PP2A activity determination
Phosphatase activity was assessed by using the malachite green-based phosphatase assay kit (Upstate Biotechnology Inc.) that measures phosphate release. Assays were run in 96-well plates, according to the manufacturer's instructions. Briefly, 25 ml per sample were incubated with 100 mM of phosphopeptide (amino-acid sequence: KRpTIRR, obtained from the kit), in total volume of 50 ml. Reaction was started by addition of the phosphopeptide and conducted for 5 min at room temperature. The reaction was stopped by the addition of 100 ml malachite green solution. After 15 min of colour development, the release of phosphate was quantified by measuring the absorbance at 650 nm in a microtiterplate reader. The amount of released phosphate (pmol) was then calculated from a standard curve (0-2000 pmol). Percentages of PP2A activity in aspirin treated cells are compared to basal PP2A activity measured in untreated cells.
Transient transfection with PP2A constructs DLD-1 were transfected with an N-terminal triple (HA)-tagged PP2A catalytic subunit C constructs (Chung et al., 1999) or GFP-tagged DNA at 6 Â 10 6 cells/transfection on a nucleofector (Amaxa, Cologne, Germany) using a standard protocol from the supplier and solution V and program T-20. The (HA) 3 -C Y307F construct contains a mutated Tyr307 of the catalytic subunit (tyrosine is mutated to a phenylalanine) to eliminate this site of phosphorylation and one wild-type catalytic subunit ((HA) 3 -C WT ) to serve as control (Chung et al., 1999) . These constructs were kindly provided by Dr DL Brautigan from the University of Virginia, Charlottesville, VA, USA. The GFP-tagged DNA serves as a transfection efficiency control. After transfection, cells were immediately seeded in a 12-well plate and the cells were allowed to adhere overnight. Subsequently, cells were treated with 5 mM of aspirin for 60 min. Afterwards, cells were washed in ice cold PBS and scraped into 100 ml of 3 Â SDS-sample buffer (125 mM Tris/ HCl, pH 6.8; 4% SDS; 2% b-mercapto ethanol; 20% glycerol, bromphenol blue). Samples were used for immunoblotting.
Statistical analysis
Statistical analysis was performed using Student's t-test and Po0.05 was considered significant. Data are expressed as the mean and standard deviation.
